Q1 FY27: Revenue up 31% YoY but PAT falls 31%, margins under pressure

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹813.50

prior close

₹745.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.1%-2.8% vs market

Pharmaceuticals peers, median of 166sector-0.4%-2.4% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.0

10m

+5.1

15m

+3.4

30m

+5.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.1-2.8-0.4-2.4

Next day

-4.0+0.2-4.2-0.3-3.7

-1.2+0.6-1.8-0.5-0.7

-3.1-0.0-3.1-1.3-1.8

-0.2+0.5-0.7-0.9+0.7

-0.9+0.8-1.7-0.4-0.5

-2.8+0.6-3.3-0.9-1.9

15d

+4.0+1.3+2.7+0.0+4.0

+7.4-1.4+8.8-0.1+7.6

+6.9-0.6+7.5-2.8+9.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supriya Lifescience reported Q1 FY27 revenue of Rs 189.75 crore, up 30.8% YoY from Rs 145.07 crore. However, PAT fell to Rs 24.04 crore from Rs 34.79 crore, a 30.9% drop. EBITDA margin compressed to about 26% from nearly 37% YoY due to higher material and other costs. EPS stood at Rs 2.99 vs Rs 4.32. Auditors gave a clean limited review. Company also flagged export material intercepted by customs.

Likely market impact

Topline growth is strong but profitability took a hit. Watch for margin recovery and resolution of the customs-detained shipment.